Advertisements



Risk-Reward With Gilead Sciences

Even with a 3% dividend yield, the stock is too expensiveCheck out Jim S.....»»

Category: smallbizSource: nytOct 18th, 2018

Gilead, Galapagos drug fails in Phase 3 clinical study

Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Thursday, the day after the company said an experimental idiopathic pulmonary fibrosis drug it was developing with Galapagos failed a Phase 3 clinical trial. Shares o.....»»

Category: topSource: marketwatchFeb 11th, 2021

$116 million call spread bought in Tesla with 50/50 risk reward

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2021

Short selling is a high-risk but high-reward trading strategy that profits from a stock price"s fall

Short sel.....»»

Category: topSource: businessinsiderFeb 4th, 2021

Earnings Results: Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4

Shares of Gilead Sciences Inc.'s stock gained 2.1% in after-hours trading on Thursday after the drug maker surprised investors with better-than-expected sales of its COVID-19 drug Veklury during the fourth quarter of 2020......»»

Category: topSource: marketwatchFeb 4th, 2021

American Airlines downgraded on balanced risk/reward at Seaport

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 1st, 2021

Barclays downgrades Canada Goose on unfavorable risk/reward after rally

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 1st, 2021

Gilead buys more Arcus Biosciences stock, at a price above the record close

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus shares were still inactive in pr.....»»

Category: topSource: marketwatchFeb 1st, 2021

Gritstone Oncology shares soar 44% premarket on news of collaboration with Gilead to develop HIV therapy

Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to us.....»»

Category: topSource: marketwatchFeb 1st, 2021

Helen of Troy downgraded to Perform at Oppenheimer on balanced risk/reward

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: worldSource: nytJan 28th, 2021

Pinduoduo downgraded to Sector Weight at KeyBanc on balanced risk/reward

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 26th, 2021

Marathon Petroleum started with Neutral at UBS on balanced risk-reward

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 26th, 2021

UBS sees "golden" risk reward for McDonald"s

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 21st, 2021

Gilead Sciences upgraded to overweight at Morgan Stanley

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJan 19th, 2021

Entercom upgraded to Overweight at Wells Fargo on compelling risk/reward

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 19th, 2021

Wells Fargo risk/reward remains attractive, says Baird

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 19th, 2021

Gilead Sciences Raises FY Guidance Due To Remdesivir Sales

CNBC Exclusive: CNBC Transcript: Gilead Sciences Chairman & CEO Daniel O.....»»

Category: blogSource: valuewalkJan 11th, 2021

Gilead updates 2020 guidance to raise sales outlook, tighten and lower top end of EPS range

Gilead Sciences Inc. updated its guidance for 2020 on Monday, raising its outlook for sales to reflect sales of COVID-19 treatment.....»»

Category: topSource: marketwatchJan 11th, 2021

3 reasons why the stock market is vulnerable to a sharp sell-off, according to Morgan Stanley

"We must acknowledge that the 'risk reward' of the US equity market has deteriorated materially and the market is ripe for a drawdown," said Morgan Stanley's Mike Wilson. .....»»

Category: dealsSource: nytJan 5th, 2021

How Iran is pursuing a high-risk/high-reward strategy to gain an edge in talks with Biden

An uptick in Iranian nuclear and naval activity is part of an effort to make sure the Biden administration prioritizes negotiations with Tehran. Iranian Revolutionary Guard members a.....»»

Category: worldSource: nytJan 4th, 2021

VistaGen upgraded on "clearly skewed" risk/reward at William Blair

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 4th, 2021